Risk Stratification of the apparently healthy population

Risk Stratification of the apparently healthy population with architect STAT HIGH SENSITIVE TROPONIN-I

DECEMBER 18, 2018

SPEAKERs

 

Image of Gillian MurtaghGillian Murtagh, MD 
Associate Medical Director, Abbott Diagnostics

 

Dr. Murtagh is Associate Medical Director of Medical and Scientific Affairs for Abbott Diagnostics. Dr. Murtagh directs and implements clinical research activities, internal and external educational programs and business development projects in the cardiac space. 

Dr. Murtagh received her MD from Trinity College Dublin in 2003 before completing residency in Internal Medicine and specialty training in Cardiology (Advanced Cardiovascular Imaging and Cardio-Oncology at Northwestern Memorial and the University of Chicago). Dr. Murtagh has been involved in cardiovascular biomarker research for over ten years. She was co-chair of the ACC Working Group in Cardio-Oncology and has authored and co-authored multiple publications on biomarkers and imaging. She joined Abbott Diagnostics Division as Associate Medical Director in 2015.

ABSTRACT

In this webinar you will hear about a recently CE marked application for ARCHITECT STAT High Sensitive Troponin I, that aids in providing greater accuracy for estimation of risk for future cardiac events in apparently healthy people, when used in conjunction with clinical and diagnostics findings. Risk is classified as low, moderate or elevated and use of ARCHITECT STAT High Sensitive Troponin I, is supported by a large body of evidence. This simple blood test can aid in earlier intervention for high risk patients and may avoid unnecessary tests and treatments in low risk patients.

ARCHITECT STAT High Sensitive Troponin I, is well known to many through its use in Emergency Departments where it has been trusted for many years to rule in or rule out Myocardial Infarction. This latest application sets the stage to support tackling the cardiovascular disease burden through prevention.

LEARNING OBJECTIVES

In this webinar, you will:

  • Understand the limitations of current risk assessment tools
  • Understand how addition of ARCHITECT STAT High Sensitive Troponin I into assessment algorithms can assist in predicting risk
  • Understand how addition of ARCHITECT STAT High Sensitive Troponin I into assessment algorithms can assist in earlier patient management for those at high risk
  • Understand how addition of ARCHITECT STAT High Sensitive Troponin I into assessment algorithms can assist in avoiding unnecessary tests and treatments in low risk patients
  • Understand how addition of ARCHITECT STAT High Sensitive Troponin I into assessment algorithms can assist in reducing the growing cost burden of cardiovascular disease
  • Understand the body of evidence

Watch The Webinar

  
 
                            

Related Resources

CARDIOVASCULAR DISEASE: A SHIFT FROM DIAGNOSIS TO PREVENTION

risk-stratification-main-image-300x200.jpg

The apparently healthy population may not know they are at risk, but when identified early, heart disease can be prevented through lifestyle changes and medications. 

Find Out More on RISK STRATIFICATION

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

DO YOU WISH TO CONTINUE AND EXIT THE CORE LABORATORY WEBSITE?

Content is not under the control of corelaboratory.abbott.

Yes No